Ylva Borgas
1 – 3 of 3
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2026
-
Mark
Certolizumab pegol, abatacept, tocilizumab or active conventional therapy in early rheumatoid arthritis: 48-week patient-reported outcomes from the NORD-STAR trial
Lampa, J. ; Cagnotto, G. LU
; Turesson, C.
LU
; Wallman, J.K.
LU
; Linge, P.
LU
; Exarchou, S.
LU
and Borgas, Y.
LU
(2026)
In The Lancet Rheumatology
8(4).
p.285-294
- Contribution to journal › Article
- 2025
-
Mark
Myocardial infarction in ANCA-associated vasculitis : A population-based cohort study
Borgas, Ylva LU
; Mohammad, Moman Aladdin
LU
; Gisslander, Karl
LU
; Rathmann, Jens
LU
; Erlinge, David
LU
; Jayne, David
and Mohammad, Aladdin J.
LU
(2025)
In RMD Open
11(2).
- Contribution to journal › Article
- 2020
-
Mark
Anti-rheumatic treatment and prosthetic joint infection : An observational study in 494 elective hip and knee arthroplasties
Borgas, Ylva LU
; Gülfe, Anders
LU
; Kindt, Mikael
and Stefánsdóttir, Anna
LU
(2020)
In BMC Musculoskeletal Disorders
21(1).
- Contribution to journal › Article